Associations - spartalizumab (PDR001)

BRAF V600	Melanoma	BRAF V600	Melanoma	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials trametinib + dabrafenib + PDR001 Sensitive : B	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials trametinib + dabrafenib + PDR001 Sensitive : B
BRAF V600 + LDH elevation	Melanoma	BRAF V600 + LDH elevation	Melanoma	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials trametinib + dabrafenib + PDR001 Sensitive : B	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials trametinib + dabrafenib + PDR001 Sensitive : B
TMB-L	Melanoma	TMB-L	Melanoma	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials trametinib + dabrafenib + PDR001 Sensitive : B	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials trametinib + dabrafenib + PDR001 Sensitive : B
BRAF V600K	Melanoma	BRAF V600K	Melanoma	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials trametinib + dabrafenib + PDR001 Sensitive : B	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials trametinib + dabrafenib + PDR001 Sensitive : B
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	trametinib + dabrafenib + PDR001 Sensitive: C2 – Inclusion Criteria trametinib + dabrafenib + PDR001 Sensitive : C2	trametinib + dabrafenib + PDR001 Sensitive: C2 – Inclusion Criteria trametinib + dabrafenib + PDR001 Sensitive : C2
PD-L1 expression	Neuroendocrine Tumor	PD-L1 expression	Neuroendocrine Tumor	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3
HAVCR2 expression	Nasopharyngeal Carcinoma	HAVCR2 expression	Nasopharyngeal Carcinoma	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3
LAG3 expression	Nasopharyngeal Carcinoma	LAG3 expression	Nasopharyngeal Carcinoma	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3
IFNG expression	Nasopharyngeal Carcinoma	IFNG expression	Nasopharyngeal Carcinoma	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3
FGFR4 expression	Hepatocellular Cancer	FGFR4 expression	Hepatocellular Cancer	PDR001 + FGF401 Sensitive: C3 – Early Trials PDR001 + FGF401 Sensitive : C3	PDR001 + FGF401 Sensitive: C3 – Early Trials PDR001 + FGF401 Sensitive : C3
KLB expression	Hepatocellular Cancer	KLB expression	Hepatocellular Cancer	PDR001 + FGF401 Sensitive: C3 – Early Trials PDR001 + FGF401 Sensitive : C3	PDR001 + FGF401 Sensitive: C3 – Early Trials PDR001 + FGF401 Sensitive : C3
MET exon 14 mutation + ALK wild-type	Non Small Cell Lung Cancer	MET exon 14 mutation + ALK wild-type	Non Small Cell Lung Cancer	capmatinib + PDR001 Sensitive: C3 – Early Trials capmatinib + PDR001 Sensitive : C3	capmatinib + PDR001 Sensitive: C3 – Early Trials capmatinib + PDR001 Sensitive : C3
MET exon 14 mutation + EGFR wild-type	Non Small Cell Lung Cancer	MET exon 14 mutation + EGFR wild-type	Non Small Cell Lung Cancer	capmatinib + PDR001 Sensitive: C3 – Early Trials capmatinib + PDR001 Sensitive : C3	capmatinib + PDR001 Sensitive: C3 – Early Trials capmatinib + PDR001 Sensitive : C3
PD-1 overexpression	Pancreatic Cancer	PD-1 overexpression	Pancreatic Cancer	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3
PD-1 overexpression	Gastric Cancer	PD-1 overexpression	Gastric Cancer	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3
PD-1 overexpression	Ovarian Cancer	PD-1 overexpression	Ovarian Cancer	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3
PD-1 overexpression	Colorectal Cancer	PD-1 overexpression	Colorectal Cancer	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3
PD-1 overexpression	Cholangiocarcinoma	PD-1 overexpression	Cholangiocarcinoma	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3
PD-1 overexpression	Sarcoma	PD-1 overexpression	Sarcoma	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3
PD-1 overexpression	Mesothelioma	PD-1 overexpression	Mesothelioma	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3	PDR001 Sensitive: C3 – Early Trials PDR001 Sensitive : C3
NRAS mutation	Melanoma	NRAS mutation	Melanoma	PDR001 + ERAS-254 Sensitive: C3 – Early Trials PDR001 + ERAS-254 Sensitive : C3	PDR001 + ERAS-254 Sensitive: C3 – Early Trials PDR001 + ERAS-254 Sensitive : C3
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	PDR001 + ERAS-254 Sensitive: C3 – Early Trials PDR001 + ERAS-254 Sensitive : C3	PDR001 + ERAS-254 Sensitive: C3 – Early Trials PDR001 + ERAS-254 Sensitive : C3

spartalizumab (PDR001)

Associations
(22)

Associations
(22)

spartalizumab (PDR001)

Associations(22)

Associations(22)

Associations
(22)

Associations
(22)